| Cell line name |
ES8-SLFN11-KO |
|---|
| Accession |
CVCL_C6N6 |
|---|
| Resource Identification Initiative |
To cite this cell line use: ES8-SLFN11-KO (RRID:CVCL_C6N6) |
|---|
| Comments |
Population: Caucasian.
Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11. |
|---|
| Sequence variations |
- Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Ewing sarcoma (NCIt: C4817)
Ewing sarcoma (ORDO: Orphanet_319) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1204 (ES8) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
10Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=34413129; DOI=10.1158/1535-7163.MCT-21-0089
Gartrell J., Mellado-Largarde M., Clay M.R., Bahrami A., Sahr N.A., Sykes A., Blankenship K., Hoffmann L., Xie J., Cho H.P., Twarog N., Connelly M., Yan K.-K., Yu J.-Y., Porter S.N., Pruett-Miller S.M., Neale G., Tinkle C.L., Federico S.M., Stewart E.A., Shelat A.A.
SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA-damaging agents.
Mol. Cancer Ther. 20:2151-2165(2021) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q116048948
|
|---|
| Entry history |
|---|
| Entry creation | 15-Dec-2022 |
|---|
| Last entry update | 21-Mar-2023 |
|---|
| Version number | 2 |
|---|
